Docoh
Loading...

GTHX G1 Therapeutics

Filed: 2 Aug 21, 7:05am

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 2, 2021 (July 27, 2021)

 

 

G1 THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware 001-38096 26-3648180
(State or other jurisdiction
of incorporation)
 (Commission
File Number)
 (IRS Employer
Identification No.)

 

 

700 Park Offices Drive

Suite 200

Research Triangle Park, NC

 

27709

 (Address of principal executive offices) (zip code)

Registrant’s telephone number, including area code: (919) 213-9835

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol

 

Name of each exchange
on which registered

Common stock, $0.0001 par value GTHX The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of New Executive Officer

On August 2, 2021, G1 Therapeutics, Inc. (the “Company”) announced the appointment of Andrew Perry as Chief Commercial Officer. Mr. Perry joins the Company from ViiV Healthcare NA, a joint venture majority-owned by GlaxoSmithKline, where he served as Vice President, US Marketing. Mr. Perry brings nearly 25 years of leadership experience in product commercialization and managed markets to the Company, having led multiple successful product launches and growing brands.

Departure of Executive Officer

On July 27, 2021, the Company and Soma Gupta, Chief Commercial Officer, mutually agreed to separate. Ms. Gupta left the Company for personal and professional reasons.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.  Description
99.1  Press Release dated August 2, 2021
104  Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

G1 THERAPEUTICS, INC.
By: 

/s/ James Stillman Hanson

 James Stillman Hanson
 General Counsel

Date: August 2, 2021